What's the outlook for TVTX's Q1 2025 earnings?

**Travere Therapeutics Inc (TVTX) is poised for a positive Q1 2025 earnings report**, and here's why: 1. **Strong Product Sales**: The company's net product sales for Q4 2024 were $74 million, with FILSPARI achieving $50 million in net product sales for the quarter. This momentum is likely to continue, driven by the successful commercial launch and full FDA approval of FILSPARI for IgAN. 2. **Potential Approval in FSGS**: Travere plans to submit a supplemental New Drug Application (sNDA) for FILSPARI in FSGS by the end of Q1 2025. If approved, FILSPARI could become the first FDA-approved treatment for FSGS, addressing a significant unmet medical need and potentially opening up a new $1 billion-plus market. 3. **Financial Position**: Travere's strong cash position, with $370.7 million in cash, cash equivalents, and marketable securities as of December 31, 2024, provides a solid buffer to support strategic initiatives and fund potential growth opportunities. 4. **Analyst Optimism**: The consensus among analysts is positive, with an average 12-month price target of $36.29, indicating potential upside from the current price. Additionally, recent analyst actions have included raises in price targets and ratings, reflecting growing confidence in Travere's prospects. In conclusion, Travere Therapeutics Inc is well-positioned for a strong Q1 2025 earnings report, driven by continued product sales momentum and potential regulatory approvals.